Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
The chemokine system represents a diverse group of G protein-coupled receptors responsible for orchestrating cell recruitment under both homeostatic and inflammatory conditions. Chemokine receptor 9 (CCR9) is a chemokine receptor known to be central for migration of immune cells into the intestine....
Main Authors: | Walters, M, Wang, Y, Lai, N, Baumgart, T, Zhao, B, Dairaghi, D, Bekker, P, Ertl, L, Penfold, M, Jaen, J, Keshav, S, Wendt, E, Pennell, A, Ungashe, S, Wei, Z, Wright, J, Schall, T |
---|---|
格式: | Journal article |
语言: | English |
出版: |
2010
|
相似书籍
-
MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
由: Ungashe, S, et al.
出版: (2008) -
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
由: Bekker, P, et al.
出版: (2007) -
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
由: Keshav, S, et al.
出版: (2007) -
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
由: Bekker, P, et al.
出版: (2009) -
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
由: Keshav, S, et al.
出版: (2009)